Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Early stage specific autoantibody panel diagnostic kit for small cell carcinoma of the lung

A technology for early diagnosis of small cell carcinoma, applied in instruments, measuring devices, scientific instruments, etc., can solve the problem of insufficient sensitivity and specificity for lung cancer screening

Active Publication Date: 2020-10-23
QIANFOSHAN HOSPITAL OF SHANDONG
View PDF1 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Second, the study found that the sensitivity and specificity of a single marker is not enough for lung cancer screening, and the combination of multiple markers is a means to obtain a high sensitivity and high specificity diagnosis

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Early stage specific autoantibody panel diagnostic kit for small cell carcinoma of the lung
  • Early stage specific autoantibody panel diagnostic kit for small cell carcinoma of the lung
  • Early stage specific autoantibody panel diagnostic kit for small cell carcinoma of the lung

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0045] Example 1 preliminary screening experiment:

[0046] Serum collection: The serum of the control group came from healthy people in the physical examination center. All lung cancer cases were diagnosed by histopathology, according to the latest WHO classification of lung cancer and the 6th edition of UICC staging criteria for lung cancer, and met: ①Patients with primary small cell carcinoma of the lung confirmed by histopathology or cytology. ②Have not received any anti-cancer treatment before blood collection. ③ All patients signed the informed consent.

[0047] First, the patient's serum was hybridized with a chip containing 1627 disease-related proteins to obtain specific binding highlights. The chip was scanned by MicroVigene software (Vigene Tech version 2.9.9.2) to obtain the optical density value. The antigenic protein specifically binding to the antibody in the detection serum was analyzed and screened by the statistical software spss17.0.

[0048] The basis fo...

Embodiment 2

[0052] Example 2 Medium screening experiment scheme:

[0053] 1) Serum collection: Serum from patients with benign lung tumors: ① No anti-cancer treatment was received before blood collection. ② All patients signed the informed consent. The inclusion criteria for all lung cancer cases were the same as the initial screening.

[0054] 2) Screening in the protein chip: Print the antigens corresponding to the 20 antibodies that have been screened on the glass slide to make a chip. Add patient serum or control serum to each chip, add rabbit anti-human secondary antibody, scan, and statistically analyze.

[0055] The basis for screening autoantibodies is: on the premise that the specificity is greater than 91%, the sensitivity is above 20%.

[0056] After intermediate screening, 10 autoantibodies were obtained, namely CDC20, CUL5, ELMOD1, ERCC2, FGF1, HOXB6, KRT8, NFE2, POLDIP3, RRAS2.

[0057] Conclusion: In the screening experiment, the above 10 autoantibodies were obtained af...

Embodiment 3

[0058] Embodiment 3 Verification stage experimental scheme:

[0059] 1) Serum collection: The principle of collection is the same as that of the primary screening stage. But there can be no repeat serum.

[0060] 2) Use the ELISA (rapid enzyme-linked immunosorbent assay) method to detect the relative expression level (OD value) of the effective antibody obtained after the intermediate screening. The method is as follows: in a 96-well plate, after incubation overnight with the antibody coated with anti-GST, the corresponding antigenic protein with the GST label is added, and the antigen is captured by the anti-GST and coated in the well plate. Then add experimental serum to incubate, finally add rabbit anti-human secondary antibody, TMB substrate color development, OD450 reading value.

[0061] The basis for screening autoantibodies: under the premise that the specificity is greater than 91%, the sensitivity is above 30%.

[0062] Conclusion: Three specific autoantibodies PO...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
Sensitivityaaaaaaaaaa
Sensitivityaaaaaaaaaa
Login to View More

Abstract

The invention discloses an early specific autoantibody panel diagnosis kit for small cell carcinoma of the lung. The kit is prepared from an antigen producing KRT8, CDC20 and POLDIP3 antibodies, a 1Msodium bicarbonate buffer solution, a PBST buffer solution, an enzyme-labeled antibody, a TMB substrate and a stop solution. The kit is high in sensitivity, strong in specificity, simple in operationand convenient in detection and has certain significance for diagnosis of the small cell carcinoma of the lung by being popularized clinically.

Description

technical field [0001] The invention relates to the technical field of medical detection reagents, in particular to a specific early autoantibody ELISA panel for small cell carcinoma of the lung. Background technique [0002] Lung cancer is also called primary bronchial lung cancer. Refers to malignant tumors originating from the bronchial mucosal epithelium. It is currently the most common and fastest-growing malignant tumor, and it is also the most serious malignant tumor that threatens human life and health, with a 5-year survival rate of 30-40%. Early diagnosis and timely treatment of lung cancer are the key to prolonging the 5-year survival period. [0003] Small cell lung cancer (SCLC small cell lung cancer) is an undifferentiated, highly malignant tumor with complex etiology, accounting for 20%-25% of primary lung cancers. Its onset age is younger, more common in men. Because small cell lung cancer is a highly malignant tumor, the biological behavior is bad, the d...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): G01N33/574
CPCG01N33/57423
Inventor 杜娟
Owner QIANFOSHAN HOSPITAL OF SHANDONG
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com